ABBV vs AVGO: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Broadcom Inc. β fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. Β· Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
Broadcom Inc. Β· Technology
$379.86
-41.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+1.2%).
AVGO trades at a lower forward P/E
(61.3x).
These are model outputs β not personalized investment advice.
See all research β
Valuation & Fundamentals
| Metric |
ABBV |
AVGO |
| Current Price |
$261.07 |
$379.86 |
| Fair Value Estimate |
$264.30 |
$223.93 |
| Upside to Fair Value |
+1.2%
|
-41.0%
|
| Market Cap |
$461.3B |
$1,806.8B |
| Forward P/E |
128.0x
|
61.3x
|
| EV / EBITDA |
31.0x
|
44.1x
|
| Price / Sales |
7.3x
|
23.9x
|
| Price / FCF |
22.1x
|
55.2x
|
| Revenue Growth YoY |
+12.4%
|
+47.9%
|
| Gross Margin |
70.7%
|
67.0%
|
| Operating Margin |
27.6%
|
43.7%
|
| Return on Equity |
68.0%
|
36.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
1.81%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a duraβ¦
Broadcom Inc. is a leading technology company specializing in semiconductors and infrastructure software, with a business split nearly evenly between these two segments. The company benefits from a durable competitive moat driven by customer concentration in mission-critical infrastructure, high switching costs, and a broad portfolio spanning semiconductors and infrastructure software. Broadcom hβ¦
Accumulation Zones
| Metric |
ABBV |
AVGO |
| Zone Low |
$198.23 |
$167.95 |
| Zone High |
$224.66 |
$190.34 |
| In Buy Zone? |
No
|
No
|